Introduction {#S0001}
============

Chronic obstructive pulmonary disease (COPD) is characterized by persistent airflow limitation and is usually progressive. Exacerbations contribute to the overall severity in the individual patient. Acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is a growing clinical problem responsible for a substantial worldwide health burden. The diagnosis of AE depends on the acute change in the patient's symptoms, including productive cough and dyspnea. The key mechanism behind AE is acute inflammation, including airway inflammation and systemic inflammation. The major medications for AECOPD are bronchodilators, corticosteroids and antibiotics. The broad-spectrum anti-inflammatory steroids carry a risk of side-effects. Two-thirds of patients admitted to intensive care units with AECOPD are treated with high doses of corticosteroids that are associated with poorer outcomes and more frequent adverse effects.[@CIT0001] Treatment of patients suffering from AECOPD is still challenging, especially when steroids and other current agents are less effective.

There is an urgent need to explore the pathophysiological mechanism of AECOPD, which will give future clues for new anti-inflammation target therapies. It has been reported that many molecules are upregulated during the AE process. Chen et al conducted a systematic review. Interleukin-6, C-reactive protein (CRP), and tumor necrosis factor-alpha were the most frequently studied biomarkers.[@CIT0002] In our previous studies, we found that levels of serum insulin-like growth factor binding protein 7 (IGFBP7) level was raised during AECOPD. Similar to the expression pattern of CRP, the IGFBP7 levels reduced after convalescence from AE.[@CIT0003] IGFBP7 belongs to IGFBP superfamily, which are a group of homologous proteins representing an important link between insulin and insulin-like growth factor (IGF) systems. IGFBP7 binds IGF at least 5- to 25-fold lower, and insulin 500-fold higher than conventional IGFBP1-6.[@CIT0004] Ye et al demonstrated that insulin-like growth factor 1 (IGF1) level was decreased in AECOPD serum.[@CIT0003],[@CIT0005] Insulin, IGF1 and IGFBP form the important insulin/IGF1/IGFBP network. However, the role of insulin in AECOPD was not clear.

Insulin is a peptide hormone produced by beta cells of the pancreatic islets. It is the main anabolic hormone of the body. Insulin participates in not only glucose control, but also many other physiological and pathophysiological processes, including lipid metabolism and the inflammation. We hypothesize that insulin functions in the AE process of COPD. In this study, we wanted to determine the level of insulin in AECOPD patients, as well as the levels of glucose and lipid. Through this approach, it is hoped to achieve a greater clarification of the role of the insulin/IGF1/IGFBP7 network in AECOPD.

Materials and methods {#S0002}
=====================

Definition of AECOPD {#S0002-S2001}
--------------------

COPD was diagnosed using the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criterion of a post-bronchodilator FEV1/FVC ratio of 70% of that predicted. Exacerbations were defined as a change in baseline dyspnea, cough or sputum production that was greater than the normal day-to-day variation and sufficient to warrant a change in management. Selected COPD patients were excluded if they were diagnosed with active pulmonary tuberculosis, cancer, interstitial lung disease, or clinically significant bronchiectasis.

Study population {#S0002-S2002}
----------------

From December 2011 to August 2014, twenty-two hospitalized AECOPD patients were enrolled, of which 4 patients were combined with diabetes. Twenty age- and sex-matched stable COPD patients and twenty age- and sex-matched healthy subjects were also enrolled, of which no one were combined with diabetes. Healthy control subjects were recruited from the general population and had normal pulmonary function (FEV1/FVC 70% and FEV1 80% of predicted). All patients gave informed consent to participate in the present study, which was approved by the Medical Ethical Committee of the Sir Run Run Shaw Hospital. Written, informed patient consent was obtained, and the study was conducted in accordance with the Declaration of Helsinki.

Study design {#S0002-S2003}
------------

A venous blood sample was obtained from patients with AECOPD within 24 h of hospitalization. Follow-up venous blood samples were obtained on the discharge day following recovery from the exacerbation. Decisions to discharge were based on GOLD guidelines,[@CIT0006] according to which a subject could leave the hospital when he was able to use inhaled bronchodilators, needed inhalation therapy with short-acting β agonists no more frequently than every 4 h, was able to walk across the room (if previously ambulatory), was able to eat and sleep without being awakened by dyspnea, had been clinically stable for 12--24 h, and had understood completely the correct use of medications, and when the subject and the physician were confident that the subject could manage successfully at home[@CIT0003] All decisions for treatment and discharge were made by the attending physicians of the department, and data on duration of stay were recorded on discharge.

Blood sampling {#S0002-S2004}
--------------

After a 12 hr overnight fast, all venous samples were collected in evacuated blood collection tubes containing Ethylene Diamine Tetraacetic Acid (EDTA), centrifuged (1500 g, 20 min) within 60 min of collection, and the supernatants stored at −70 °C until required. The separated plasma sample was aliquoted into sterile microcentrifuge tubes (500 μl per vial) and were then stored at −80 °C.

Biochemical measurements {#S0002-S2005}
------------------------

Insulin was detected by chemiluminescence immunoassay (Beckman Coulter DIX800, USA). Glucose was analyzed by the hexokinase method, triglycerides (TG) by the glycerol phosphate oxidase method, total cholesterol (CHOL) by the CHOD-PAP method, low-density lipoprotein cholesterol (LDL-CHOL) by surfactant assay, high density lipoprotein cholesterol (HDL-CHOL) by CAT assay. They were detected by Abbott Architect c16000, USA.

Statistical analyses {#S0003}
====================

Quantitative data were expressed as means±standard deviations (SD). Differences between subject groups were measured by one-way analysis of variance (ANOVA) with post-hoc analysis performed using Tamhane's test. For the comparison of insulin and glucose level on admission and at discharge, paired Student's *t* test was used. *P*-values ＜0.05 were deemed to indicate statistical significance. Correlations between continuous variables were assessed by the Spearman partial correlation coefficient (rs). All statistical analyses were performed using SPSS for Windows, version 20.0 (SPSS Inc, Chicago, IL, USA).

Results {#S0004}
=======

Baseline characteristics of AECOPD patients and control subjects {#S0004-S2001}
----------------------------------------------------------------

The study included 22 AECOPD patients, 20 stable COPD patients and 20 healthy controls. Baseline characteristics of the patients and the controls were summarized in [Table 1](#T0001){ref-type="table"}. Table 1Baseline characteristics of the patients and the controlsAECOPD (n=22)COPD (n=20)Healthy (n=20)*P*-valueAge74.86±5.3670.9±8.1468.75±4.14*P*\>0.05Men:women18:415:516:4*P*\>0.05Ever-smoker161615*P*\>0.05BMI (kg/m^2^)20.88±2.5420.83±2.1621.29±1.23*P*\>0.05FEV1(%)43.23±11.2249.02±15,788.15±5.28*P*\<0.05[^1][^2]

Insulin level, glucose level and homeostasis model assessment of insulin resistance (HOMA-IR) of AECOPD patients were higher than healthy controls {#S0004-S2002}
--------------------------------------------------------------------------------------------------------------------------------------------------

Eighteen AECOPD patients without diabetes were enrolled. Insulin levels in AECOPD patients and COPD patients were higher than that in healthy controls (7.19±6.02 and 6.52±2.56 vs 3.28±1.09 μIU/mL, *P*\<0.05). The glucose levels in AECOPD patients were also higher than that in stable COPD and healthy controls (126.61±50.9 vs 95.58±11.44 and 96.21±12.66 mg/dL, *P*\<0.05). HOMA-IR=fast glucose (mmol/L)×fast insulin (μIU/mL)/22.5. The HOMA-IR in AECOPD patients and stable COPD patients were higher than that in healthy controls(2.66±2.72 and 1.52±0.53 vs 0.78±0.26, *P*\<0.05). The HbA1c levels of the three groups were all below 6.4% (5.77±0.43%, 5.45±0.63%, 5.47±0.41%, [Figure 1](#F0001){ref-type="fig"}).Figure 1Serum glucose, insulin concentrations and HOMA-IR index in AECOPD patients, stable COPD patients and the health controls.**Notes:** (**A**) comparison of glucose level; (**B**) comparison of insulin level; (**C**) comparison of HOMA-IR. Differences between subject groups were measured by ANOVA with post-hoc analysis performed using Tamhane's test. (**D**) Comparison of HbA1C (%). \**P*-values ＜0.05.**Abbreviations:** AECOPD, acute exacerbation of chronic obstructive pulmonary disease; HOMA-IR, homeostasis model assessment of insulin resistance; ANOVA, one-way analysis of variance.

TG, CHOL, LDL-CHOL levels was decreased in AECOPD patients {#S0004-S2003}
----------------------------------------------------------

With regard to serum lipids, levels of TG, CHOL, and LDL-CHOL were decreased in AECOPD patients compared with healthy controls (0.78±0.33 vs 1.05±0.35 mmol/L, *P*\<0.05, 3.88±0.72 vs 4.49±0.7mmol/L, *P*\<0.05, 2.01±0.59 vs 2.59±0.58mmol/L, *P*\<0.05, respectively). The variation of HDL-CHOL levels reached no significance (1.27±0.37 vs 1.2±0.2 mmol/L, *P*\>0.05, [Figure 2](#F0002){ref-type="fig"}). While for stable COPD patients, the TG, CHOL, LDL-CHOL and HDL-CHOL levels were 1.15±0.65 mmol/L, 3.51±0.69mmol/L, 1.67±0.42 mmol/L and 1.06±0.27 mmol/L, respectively.Figure 2Serum lipids levels of AECOPD patients, stable COPD patients and the health controls.**Notes:** (**A**) comparison of TG level. (**B**) comparison of CHOL level. (**C**) comparison of LDL-CHOL level. (**D**) comparison of HDL-CHOL level. Differences between subject groups were measured by ANOVA with post-hoc analysis performed using Tamhane's test. \**P*-values ＜0.05.**Abbreviations:** TG, triglycerides; CHOL, total cholesterol; LDL-CHOL, low density lipoprotein cholesterol；HDL-CHOL, high density lipoprotein cholesterol; AECOPD, acute exacerbation of chronic obstructive pulmonary disease; ANOVA, one-way analysis of variance.

In AECOPD patients, the insulin level increased after recovery {#S0004-S2004}
--------------------------------------------------------------

The blood samples of the 22 AECOPD patients were obtained both on the admission day of AE and on the discharge day after recovery. Serum insulin and glucose levels were measured. After recovery from AE, the insulin level increased (10.67±6.22 vs 7.12±6.19 μIU/mL, *P*\<0.05) while the glucose levels decreased (122.69±41.41 vs 134.08±53.19 mg/dL, *P*\>0.05 [Figure 3](#F0003){ref-type="fig"}). The variation in glucose level was not as great as expected.Figure 3Serum insulin and glucose levels during exacerbations and after recovery in AECOPD patients.**Notes:** (**A**) Comparison of insulin level; (**B**) Comparison of glucose level; (**C**) Change of insulin level during exacerbations and after clinical recovery in 22 AECOPD patients; (**D**) Change of glucose level during exacerbations and after clinical recovery in 22 AECOPD patients. Differences between groups were measured by paired Student\'s *t*-test. \**P*-values ＜0.05.

Correlation of the amplitude of insulin variation with the amplitude of glucose variation during AE and after recovery {#S0004-S2005}
----------------------------------------------------------------------------------------------------------------------

Using the data of insulin and glucose levels during AE and after recovery, we calculated the variation amplitude of insulin and glucose. We analyzed the correlation of the amplitude of insulin variation (recovery-AE) with the amplitude of glucose variation (AE-recovery). On the basis of the scatter diagram, we observed no significant linear correlation (r=−0.184, *P*=0.41, [Figure 4](#F0004){ref-type="fig"}).Figure 4Correlation of amplitude of insulin's variation with amplitude of glucose's variation during AE and after recovery.**Notes:** Insulin's variation: recovery-AE； glucose's variation: AE-recovery. Spearman correlation analysis was performed (r=−0.184, *P*=0.41).

Discussion {#S0005}
==========

Different from hyperinsulinemia and hyperlipidemia in diseases like coronary heart disease and type 2 diabetes,[@CIT0007] we detected hyperinsulinemia and hypolipidemia in COPD patients, indicating the different pathological state of the disease. Insulin regulates the metabolism of carbohydrates, fats and proteins by promoting the absorption of carbohydrates. Also, insulin is one of the central homeostatic hormones with global effects outside the glucose and lipid metabolism pathways. Hyperinsulinemia has been demonstrated to have adverse effects on airway structure and function.[@CIT0008],[@CIT0009] In fact, the possible role of insulin in airway inflammation has already been demonstrated. Inhaled insulin in diabetic patients is associated with a decrease in forced expiratory volume in 1 second (FEV1). Patients with asthma or COPD were excluded from this therapy.[@CIT0010],[@CIT0011] The relation of hypolipemia with COPD has also been explored. A previous study has reported that low CHOL levels were significantly associated with increased mortality after AECOPD.[@CIT0012]

We first reported that after recovery from AE, the serum insulin level significantly increased. The glucose level decreased a little, but the variation was not as great as expected. Out of expect, the correlation analysis resulted in negative correlation. The lipid level variation during AE and after convalescence was not significant (data not shown).The phenomenon indicated "the downregulated role" of insulin during AE was beyond glucose and lipid control. Interestingly, the direction and amplitude of the insulin's variation was not the same for every patient. Future work is needed to explore this inconsistency.

Our finding of the downregulated level of insulin during AE, together with the previous result of increased levels of IGFBP7 and decreased IGF1 levels in the serum of AECOPD patients,[@CIT0003],[@CIT0005] indicated the potential for an "insulin-IGF1-IGFBP7 flow" occurring during AECOPD ([Figure 5](#F0005){ref-type="fig"}). The insulin/IGFBP/IGF1 network may serve as a potential target for the development of compounds to better manage AECOPD patients. Interestingly, a previous study has discussed the therapeutic value of various strategies targeting the IGF1 and IGFBP3 signaling pathways for the management of asthma, another chronic airway disease.[@CIT0013] An IGFBP3 mutant that does not bind IGF1 but binds to IGFBP-3R and acts as an IGFBP-3R agonist thus enhances the IGFBP-3R--mediated anti-inflammatory responses.[@CIT0014]Figure 5Putative mechanism of insulin-IGF1-IGFBP7 network in AECOPD.**Notes:** During AE: insulin and IGF1 flow from blood circulation to airway. IGFBP7 flows from airway to blood circulation. Recover from AE: insulin and IGF1 flow from airway to blood circulation. IGFBP7 flows from blood circulation to airway.**Abbreviations:** AE, acute exacerbation; IGFBP7, insulin-like growth factor binding protein 7; IGF1, insulin-like growth factor 1; IR, insulin receptor; IGF1R, insulin-like growth factor 1 receptor.

Our findings indicate a potentially important role of insulin in AE. According to our findings, we think that the future direction should be toward: 1) The mechanisms of how the insulin/IGF1/IGFBP7 network influences airway elements to produce structural and functional changes in COPD during AE. 2)Whether targeting the hyperinsulinemia and hypolipemia in COPD could reduce the AE frequency. 3) The therapeutic potential of targeting the insulin/IGFBP7/IGF1 network in AECOPD.
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